Role of the nuclear factor erythroid 2-related factor 2/heme oxygenase-1 signaling pathway in alcoholic liver disease

Cheng MA; Hui YANG

doi:10.3969/j.issn.1001-5256.2023.07.028

Volume 39 Issue 7

Jul. 2023

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2023 > 39(7): 1708-1713

PDF( 2315 KB)

Role of the nuclear factor erythroid 2-related factor 2/heme oxygenase-1 signaling pathway in alcoholic liver disease

DOI: 10.3969/j.issn.1001-5256.2023.07.028

Cheng MA¹,
Hui YANG^{2
,
,
,}

1.
Graduate School of Shanxi Medical University, Taiyuan 030001, China
2.
Department of Infectious Diseases, The First Hospital of Shanxi Medical University, Taiyuan 030001, China

Research funding:

Scientific Research Project of Shanxi Province Raises Funds to Support Overseas Students (2020-168)

More Information

Corresponding author: YANG Hui, 576371816@qq.com (ORCID: 0000-0002-9162-6951)
Received Date: 2022-09-20
Accepted Date: 2022-11-21
Published Date: 2023-07-20

Abstract

Abstract

The incidence rate of alcoholic liver disease (ALD) is increasing year by year China, and there is a gradual increase in disease burden among Chinese people. Oxidative stress response in hepatocytes is an important pathogenic mechanism of ALD. The nuclear factor erythroid 2-related factor 2 (Nrf2)/heme oxygenase-1 (HO-1) signaling pathway is an important endogenous anti-oxidative stress pathway in the body, and Nrf2 is activated in response to oxidative stress and exerts its transcriptional activity to induce high HO-1 expression. HO-1 is an important oxidative stress response protein and plays a role in anti-inflammation, anti- oxidation, and cell apoptosis regulation together with heme hydrolysis products (bilirubin, carbon monoxide, and iron). This article reviews the research advances in the role of the Nrf2/HO-1 signaling pathway in ALD in recent years, so as to find a theoretical basis for the development and progression of ALD and an entry point for treatment.
- Liver Diseases, Alcoholic,
- NF-E2-Related Factor 2,
- Heme Oxygenase-1,
- Signal Transduction

FullText(HTML)

References(36)

References

[1]	Fatty Liver Expert Committee, Chinese Medical Doctor Association, National Workshop on Fatty Liver and Alcoholic Liver Disease, Chinese Society of Hepatology, Chinese Medical Association. Guidelines of prevention and treatment for alcoholic liver disease: a 2018 update[J]. J Clin Hepatol, 2018, 34(5): 939-946. DOI: 10.3969/j.issn.1001-5256.2018.05.006. 中国医师协会脂肪性肝病专家委员会, 中华医学会肝病学分会脂肪肝和酒精性肝病学组. 酒精性肝病防治指南(2018年更新版)[J]. 临床肝胆病杂志, 2018, 34(5): 939-946. DOI: 10.3969/j.issn.1001-5256.2018.05.006.
[2]	SILVA-ISLAS CA, MALDONADO PD. Canonical and non-canonical mechanisms of Nrf2 activation[J]. Pharmacol Res, 2018, 134: 92-99. DOI: 10.1016/j.phrs.2018.06.013.
[3]	SHAW P, CHATTOPADHYAY A. Nrf2-ARE signaling in cellular protection: Mechanism of action and the regulatory mechanisms[J]. J Cell Physiol, 2020, 235(4): 3119-3130. DOI: 10.1002/jcp.29219.
[4]	ZHANG A, SUZUKI T, ADACHI S, et al. Distinct regulations of HO-1 gene expression for stress response and substrate induction[J]. Mol Cell Biol, 2021, 41(11): e0023621. DOI: 10.1128/MCB.00236-21.
[5]	RYTER SW. Heme oxygenase-1: An anti-inflammatory effector in cardiovascular, lung, and related metabolic disorders[J]. Antioxidants (Basel), 2022, 11(3): 555. DOI: 10.3390/antiox11030555.
[6]	ZHOU J, ZHENG Q, CHEN Z. The Nrf2 pathway in liver diseases[J]. Front Cell Dev Biol, 2022, 10: 826204. DOI: 10.3389/fcell.2022.826204.
[7]	SHERIFF L, KHAN RS, SABORANO R, et al. Alcoholic hepatitis and metabolic disturbance in female mice: a more tractable model than Nrf2^-/- animals[J]. Dis Model Mech, 2020, 13(12): dmm046383. DOI: 10.1242/dmm.046383.
[8]	WANG G, FU Y, LI J, et al. Aqueous extract of Polygonatum sibiricum ameliorates ethanol-induced mice liver injury via regulation of the Nrf2/ARE pathway[J]. J Food Biochem, 2021, 45(1): e13537. DOI: 10.1111/jfbc.13537.
[9]	WANG X, CHANG X, ZHAN H, et al. Curcumin and Baicalin ameliorate ethanol-induced liver oxidative damage via the Nrf2/HO-1 pathway[J]. J Food Biochem, 2020. DOI: 10.1111/jfbc.13425.[Online ahead of print]
[10]	FERDOUSE A, CLUGSTON RD. Pathogenesis of alcohol-associated fatty liver: lessons from transgenic mice[J]. Front Physiol, 2022, 13: 940974. DOI: 10.3389/fphys.2022.940974.
[11]	OSNA NA, DONOHUE TM Jr, KHARBANDA KK. Alcoholic liver disease: pathogenesis and current management[J]. Alcohol Res, 2017, 38(2): 147-161.
[12]	SEEN S. Chronic liver disease and oxidative stress - a narrative review[J]. Expert Rev Gastroenterol Hepatol, 2021, 15(9): 1021-1035. DOI: 10.1080/17474124.2021.1949289.
[13]	CHEN WY, SHU FM, WANG H, et al. Role of the cytochrome P450 family in metabolic-associated liver diseases[J]. J Chin Hepatol, 2022, 38(9): 2182-2187. DOI: 10.3969/j.issn.1001-5256.2022.09.045. 陈玮钰, 舒发明, 王涵, 等. 细胞色素P450家族在肝脏代谢相关疾病中的作用[J]. 临床肝胆病杂志, 2022, 38(9): 2182-2187. DOI: 10.3969/j.issn.1001-5256.2022.09.045.
[14]	WU KC, LIU J, KLAASSEN CD. Role of Nrf2 in preventing ethanol-induced oxidative stress and lipid accumulation[J]. Toxicol Appl Pharmacol, 2012, 262(3): 321-329. DOI: 10.1016/j.taap.2012.05.010.
[15]	PALIPOCH S, KOOMHIN P, PUNSAWAD C, et al. Heme oxygenase-1 alleviates alcoholic liver steatosis: histopathological study[J]. J Toxicol Pathol, 2016, 29(1): 7-15. DOI: 10.1293/tox.2015-0035.
[16]	BUKO V, ZAVODNIK I, BUDRYN G, et al. Chlorogenic acid protects against advanced alcoholic steatohepatitis in rats via modulation of redox homeostasis, inflammation, and lipogenesis[J]. Nutrients, 2021, 13(11). DOI: 10.3390/nu13114155.
[17]	TOROK NJ. Update on alcoholic hepatitis[J]. Biomolecules, 2015, 5(4): 2978-2986. DOI: 10.3390/biom5042978.
[18]	HOSSEINI N, SHOR J, SZABO G. Alcoholic hepatitis: a review[J]. Alcohol Alcohol, 2019, 54(4): 408-416. DOI: 10.1093/alcalc/agz036.
[19]	RAMOS-TOVAR E, MURIEL P. Free radicals, antioxidants, nuclear factor-E2-related factor-2 and liver damage[J]. J Appl Toxicol, 2020, 40(1): 151-168. DOI: 10.1002/jat.3880.
[20]	GALICIA-MORENO M, LUCANO-LANDEROS S, MONROY-RAMIREZ HC, et al. Roles of Nrf2 in liver diseases: molecular, pharmacological, and epigenetic aspects[J]. Antioxidants (Basel), 2020, 9(10): 980. DOI: 10.3390/antiox9100980.
[21]	HONG DG, SONG GY, EOM CB, et al. Loss of ERdj5 exacerbates oxidative stress in mice with alcoholic liver disease via suppressing Nrf2[J]. Free Radic Biol Med, 2022, 184: 42-52. DOI: 10.1016/j.freeradbiomed.2022.03.027.
[22]	RYTER SW. Heme oxgenase-1, a cardinal modulator of regulated cell death and inflammation[J]. Cells, 2021, 10(3): 515. DOI: 10.3390/cells10030515.
[23]	LIU S, TIAN L, CHAI G, et al. Targeting heme oxygenase-1 by quercetin ameliorates alcohol-induced acute liver injury via inhibiting NLRP3 inflammasome activation[J]. Food Funct, 2018, 9(8): 4184-4193. DOI: 10.1039/c8fo00650d.
[24]	ZHANG Y, WU Y, SHEN W, et al. Crosstalk between NK cells and hepatic stellate cells in liver fibrosis (Review)[J]. Mol Med Rep, 2022, 25(6): 208. DOI: 10.3892/mmr.2022.12724.
[25]	LI T, LIU HB, HU WY, et al. Role of inflammation in hepatic fibrosis[J]. J Clin Hepatol, 2022, 38(10): 2368-2372. DOI: 10.3969/j.issn.1001-5256.2022.10.032. 李婷, 刘华宝, 胡文艳, 等. 炎症在肝纤维化中的作用[J]. 临床肝胆病杂志, 2022, 38(10): 2368-2372. DOI: 10.3969/j.issn.1001-5256.2022.10.032.
[26]	CHENG ML, LU YF, CHEN H, et al. Liver expression of Nrf2-related genes in different liver diseases[J]. Hepatobiliary Pancreat Dis Int, 2015, 14(5): 485-491. DOI: 10.1016/s1499-3872(15)60425-8.
[27]	NUNES DOS SANTOS K, FLORENTINO RM, FRANÇA A, et al. Polymorphism in the promoter region of NFE2L2 gene is a genetic marker of susceptibility to cirrhosis associated with alcohol abuse[J]. Int J Mol Sci, 2019, 20(14): 3589. DOI: 10.3390/ijms20143589.
[28]	NI YH, HUO LJ, LI TT. Antioxidant axis Nrf2-keap1-ARE in inhibition of alcoholic liver fibrosis by IL-22[J]. World J Gastroenterol, 2017, 23(11): 2002-2011. DOI: 10.3748/wjg.v23.i11.2002.
[29]	LIU Y, KUANG Q, DAI X, et al. Deficiency in inactive rhomboid protein2 (iRhom2) alleviates alcoholic liver fibrosis by suppressing inflammation and oxidative stress[J]. Int J Mol Sci, 2022, 23(14): 7701. DOI: 10.3390/ijms23147701.
[30]	YANG H, ZHANG L, CHEN J, et al. Heme oxygenase-1 inhibits the proliferation of hepatic stellate cells by activating PPARγ and suppressing NF-κB[J]. Comput Math Methods Med, 2022, 2022: 8920861. DOI: 10.1155/2022/8920861.
[31]	BUCHANAN R, SINCLAIR J. Alcohol use disorder and the liver[J]. Addiction, 2021, 116(5): 1270-1278. DOI: 10.1111/add.15204.
[32]	GANNE-CARRIÉ N, NAHON P. Hepatocellular carcinoma in the setting of alcohol-related liver disease[J]. J Hepatol, 2019, 70(2): 284-293. DOI: 10.1016/j.jhep.2018.10.008.
[33]	ZHANG C, LI L, HOU S, et al. Astragaloside Ⅳ inhibits hepatocellular carcinoma by continually suppressing the development of fibrosis and regulating pSmad3C/3L and Nrf2/HO-1 pathways[J]. J Ethnopharmacol, 2021, 279: 114350. DOI: 10.1016/j.jep.2021.114350.
[34]	ZOU C, ZOU C, CHENG W, et al. Heme oxygenase-1 retards hepatocellular carcinoma progression through the microRNA pathway[J]. Oncol Rep, 2016, 36(5): 2715-2722. DOI: 10.3892/or.2016.5056.
[35]	RAGHUNATH A, SUNDARRAJ K, ARFUSO F, et al. Dysregulation of Nrf2 in hepatocellular carcinoma: role in cancer progression and chemoresistance[J]. Cancers (Basel), 2018, 10(12): 481. DOI: 10.3390/cancers10120481.
[36]	WU MM, HSIEH FI, HSU LI, et al. GT-repeat polymorphism in the HO-1 gene promoter Is associated with risk of liver cancer: a follow-up study from arseniasis-endemic areas in Taiwan[J]. J Clin Med, 2021, 10(7): 1489. DOI: 10.3390/jcm10071489.

Relative Articles

[1]	Guodong SHI, Zipeng LU, Kuirong JIANG. Diagnosis and treatment of dyspepsia associated with pancreatic tumors[J]. Journal of Clinical Hepatology, 2023, 39(12): 2770-2774. doi: 10.3969/j.issn.1001-5256.2023.12.004
[2]	Yi YAN, Junmei JIA, Yarong GUO. Role of cancer-associated fibroblasts in drug resistance of pancreatic cancer[J]. Journal of Clinical Hepatology, 2022, 38(5): 1203-1208. doi: 10.3969/j.issn.1001-5256.2022.05.048
[3]	Yiyi ZHANG, Min XU. Research advances in the mechanism of tumor microenvironment in pancreatic cancer and related targeted therapy[J]. Journal of Clinical Hepatology, 2022, 38(4): 965-968. doi: 10.3969/j.issn.1001-5256.2022.04.046
[4]	Lina BAI, Ying LIU, Chunxiao TANG, Hongxin PIAO, Zhenhua LIN, Wanshan YANG, Aihua JIN. Mechanism of carrimycin in regulating the biological function of pancreatic cancer cells[J]. Journal of Clinical Hepatology, 2022, 38(12): 2793-2801. doi: 10.3969/j.issn.1001-5256.2022.12.020
[5]	Jing WANG, Bin TAN, Zhijie ZHAO, Haochen ZHONG, Linlin QU. Genomic profile of pancreatic tumor in the coastal regions of Eastern China: A multicenter analysis of 40 cases[J]. Journal of Clinical Hepatology, 2022, 38(2): 409-414. doi: 10.3969/j.issn.1001-5256.2022.02.028
[6]	Feiyu ZHANG, Yakepu ADILA, Jinming ZHAO, Yanhang GAO. New advances in the treatment of pancreatic cancer by targeting tumor microenvironment[J]. Journal of Clinical Hepatology, 2021, 37(9): 2246-2248. doi: 10.3969/j.issn.1001-5256.2021.09.049
[7]	Zhang Yu, Jiang JianXin. Biological role of hypoxic microenvironment in pancreatic cancer[J]. Journal of Clinical Hepatology, 2020, 36(3): 708-712. doi: 10.3969/j.issn.1001-5256.2020.03.054
[8]	Wang Kun, ABUDUREYIMU·Tuerhong, Yang Fan, Liu YaHui, Fu Yu, Zhang Wei. Endoscopic pancreatic stent placement combined with tumor enucleation for benign pancreatic neck tumor: A case report[J]. Journal of Clinical Hepatology, 2019, 35(1): 185-186. doi: 10.3969/j.issn.1001-5256.2019.01.040
[9]	Yang GuiMin, Zhao YunSheng, Wang ChunHua, Jin Liang. Research advances in tumor markers for the diagnosis of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2018, 34(1): 199-203. doi: 10.3969/j.issn.1001-5256.2018.01.044
[10]	Zheng SuLi, Zhang TaiPing. An excerpt of laparoscopic surgery for pancreatic neoplasms: the European Association for Endoscopic Surgery clinical consensus conference（2017）[J]. Journal of Clinical Hepatology, 2017, 33(5): 816-819. doi: 10.3969/j.issn.1001-5256.2017.05.004
[11]	Lu: Yan, Zhang XiaoWen. Classification and diagnosis of pancreatic cystic neoplasm[J]. Journal of Clinical Hepatology, 2016, 32(5): 968-971. doi: 10.3969/j.issn.1001-5256.2016.05.039
[12]	Liu Xu, Guo XiaoZhong. Early diagnosis of pancreatic cancer[J]. Journal of Clinical Hepatology, 2016, 32(5): 864-866. doi: 10.3969/j.issn.1001-5256.2016.05.008
[13]	Yang XiaoXiao, Ma Hong. Research advances in tumor markers of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2016, 32(4): 811-815. doi: 10.3969/j.issn.1001-5256.2016.04.047
[14]	Li Zhao, Zhu JiYe. Treatment of pancreatic neuroendocrine tumor with liver metastases[J]. Journal of Clinical Hepatology, 2015, 31(5): 668-670. doi: 10.3969/j.issn.1001-5256.2015.05.007
[15]	Hou XiaoJia, Jin ZhenDong. Progress in additional new techniques of endoscopic ultrasound in treatment of pancreatic tumors[J]. Journal of Clinical Hepatology, 2015, 31(5): 671-673. doi: 10.3969/j.issn.1001-5256.2015.05.008
[16]	Group of Pancreas Surgery, Chinese Society of Surgery, Chinese Medical Association. Guidelines for the management of pancreatic neuroendocrine neoplasms (2014)[J]. Journal of Clinical Hepatology, 2014, 30(12): 1246-1248. doi: 10.3969/j.issn.1001-5256.2014.12.004
[17]	Li XiaoQing, Qian JiaMing. Differentiation between gastrointestinal neuroendocrine tumors and pancreatic neuroendocrine tumors[J]. Journal of Clinical Hepatology, 2013, 29(7): 492-495. doi: 1001-5256 (2013) 07-0492-04
[18]	Chen Jie. Pathological and differential diagnoses of exocrine pancreatic tumors[J]. Journal of Clinical Hepatology, 2013, 29(1): 45-49.
[19]	Zhang WenYing, Jin ZhenDong. Endoscopic ultrasound -guided treatment for pancreatic tumor[J]. Journal of Clinical Hepatology, 2012, 28(8): 573-575+578.
[20]	Wang YaJun, Sun JiaBang. Experience in diagnosis and treatment of pancreatic cystic tumors[J]. Journal of Clinical Hepatology, 2010, 26(5): 472-475+489.

Supplements(0)

Cited By

Cited by

Periodical cited type(12)

1.	陶丽莹，王宏光，郭庆梅，朴连玉，郭享，阮丽斌，刘时助，孙震. 内镜逆行胰胆管造影联合eyeMax胆胰成像系统直视下液电碎石治疗困难胆管结石效果观察. 临床肝胆病杂志. 2024(02): 351-355 . 本站查看
2.	刘姣，朱巧，范建梅. 内镜逆行胰胆管造影术中使用胰胆直视成像系统联合激光碎石治疗胆总管复杂结石的分析. 医学研究与战创伤救治. 2024(02): 177-180 .
3.	刘晓艳，杨亚苹，韩文雄. 多层螺旋计算机断层扫描技术与磁共振胰胆管造影技术诊断胆总管结石的临床价值. 包头医学. 2024(02): 10-12 .
4.	马丽娜·阿新拜，张立平，王林恒，王允亮，陈润花，孟捷，胡立明，姚玉璞. 经ERCP联合SpyGlass DS治疗的74例不明原因胆管狭窄患者的临床特征分析. 胃肠病学和肝病学杂志. 2024(08): 1037-1044 .
5.	艾合买江·库尔班江，布娅·米然别克，王秋玲，李得阳，高峰. SpyGlass DS系统联合激光碎石法与常规分次治疗胆总管大结石的效果和安全性的对比分析. 中国内镜杂志. 2024(08): 12-17 .
6.	郭志新，王俊，余晓，关天佑，于芳芳. NTrap网篮联合输尿管软镜钬激光术治疗上段输尿管结石的效果及预后观察. 医药论坛杂志. 2024(16): 1703-1707 .
7.	叶国华，姜继豪，王小方. 腹腔镜下联合胆道镜、术中超声及液电碎石仪治疗复杂肝内胆管结石的效果. 中国当代医药. 2024(31): 20-23 .
8.	刘杨军，李纪男. ERCP治疗高龄胆总管结石的效果. 中国老年学杂志. 2024(24): 5935-5937 .
9.	王毅兰，李喆楠，王军民. SpyGlass在胆胰疾病诊治中的研究进展. 河北医科大学学报. 2023(02): 241-245 .
10.	刘炯，汪向飞，江斌. SpyGlass系统在困难胆囊腹腔镜胆囊切除术中的应用价值. 临床外科杂志. 2023(10): 925-927 .
11.	濮天，陈江明，郭旗，蒋东，李子寒，刘付宝，耿小平. 精准肝切除术治疗复发性单侧肝内胆管结石的临床疗效及预后影响因素分析. 中华消化外科杂志. 2022(02): 273-280 .
12.	陈安，柏强善，谭凯. 对胆囊结石合并胆总管结石的老年患者实施腹腔镜胆囊切除术联合内镜逆行胰胆管造影术的临床疗效. 中国内镜杂志. 2022(11): 57-64 .